Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc. on January 19, 2023. Shoreline will pay Editas Medicine an unknown upfront payment at the close of the transaction. Additionally, Editas Medicine is eligible to receive future development and commercial milestone and royalty payments for each of the iNK programs and for future programs engineered with the gene editing technologies Under the terms of the agreement, Shoreline will obtain an exclusive license to Editas Medicine?s interest in SLEEK gene editing knock-in technology for use in Shoreline?s iNKplatform and for oncology in its iMACs platform, and on a non-exclusive basis for iMACs in other indications.

Shoreline will also receive a non-exclusive license for the use of Editas Medicine?s engineered AsCas12a enzyme. As part of the transaction, Shoreline will acquire EDIT-202, Editas Medicine?s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors, as well as an additional iNK program under development and certain related manufacturing technologies. The acquisition of Editas Medicine wholly owned oncology assets by Shoreline is part of Editas Medicine?s strategic portfolio reprioritization, including its focus on the development of in vivo gene edited medicines.

Evercore Group LLC acted as financial advisor to Editas Medicine on the transaction.